New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

Palatin Technologies to Present at 14th Annual BIO CEO & Investor Conference

CRANBURY, N.J., Feb. 9, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 at 8:30 a.m. ET.  Hosted by the Biotechnology Industry Organization (BIO), the 14th Annual BIO CEO & Investor Conference will take place February 13-14 at the Waldorf=Astoria Hotel, New York, NY. 

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin’s corporate and development programs.  Palatin Technologies has an ongoing Phase 2B clinical trial with bremelanotide, a peptide melanocortin receptor agonist, for treatment of female sexual dysfunction in premenopausal women. A live audio broadcast will be available on the “Investors” section of Palatin’s website at www.palatin.com. The live audio broadcast will be available through February 20, 2012.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin’s website at www.palatin.com.

SOURCE Palatin Technologies, Inc.

Scroll to Top